RXST vs. SLNO

In the year-to-date period, RXST achieves a -10.62% return, which is significantly lower than SLNO's 5.63% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for RxSight, Inc. (RXST) and Soleno Therapeutics, Inc. (SLNO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RXST Sharpe Ratio is -0.87, which is lower than the SLNO Sharpe Ratio of 0.04. The chart below compares the historical Sharpe Ratios of RXST and SLNO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RXST nor SLNO has paid dividends to shareholders.

The maximum RXST drawdown since its inception was -53.63%, smaller than the maximum SLNO drawdown of -99.86%. Use the drawdown chart below to compare losses from any high point for RXST and SLNO. For additional features, visit the drawdowns tool.

RxSight, Inc. (RXST) and Soleno Therapeutics, Inc. (SLNO) have volatilities of 11.15% and 11.05%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between RxSight, Inc. and Soleno Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.